PMID- 27449794
OWN - NLM
STAT- MEDLINE
DCOM- 20170829
LR  - 20170829
IS  - 1875-6638 (Electronic)
IS  - 1573-4064 (Linking)
VI  - 13
IP  - 1
DP  - 2016
TI  - The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine 
      Candidates Against Group A Streptococcus.
PG  - 22-27
LID - 10.2174/1573406412666160720093138 [doi]
AB  - BACKGROUND: Group A streptococcus (GAS) is an exclusively human pathogenic 
      bacteria. A delay in treatment of GAS infection often lead to severe diseases 
      such as rheumatic heart disease which attributes to hundreds of thousands deaths 
      annually. For the past few decades, the quest for a commercial GAS vaccine has 
      been futile. Currently one of the most investigated strategies to develop vaccine 
      against GAS includes the use of conserved epitopes from major virulent factor of 
      GAS, M-protein. METHODS: In this study, cationic liposomes of various sizes (70 
      nm to 1000 nm) were prepared with dimethyldioctadecylammonium bromide (DDAB) 
      encapsulating lipopeptide bearing M-protein derived B-cell epitope (J14). 
      RESULTS: Smaller liposomes induced higher antibody titres, though the differences 
      between groups were not statistically significant. CONCLUSION: Nonetheless, all 
      mice which were immunized with liposome-lipopeptide delivery system elicited high 
      levels of systemic (IgG) and mucosal antibodies (IgA), which were discernably 
      higher than those induced with the help of commercial adjuvant (cholera toxin B 
      subunit).
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.org.
FAU - Ghaffar, Khairunnisa A
AU  - Ghaffar KA
FAU - Marasini, Nirmal
AU  - Marasini N
FAU - Giddam, Ashwini K
AU  - Giddam AK
FAU - Batzloff, Michael R
AU  - Batzloff MR
FAU - Good, Michael F
AU  - Good MF
FAU - Skwarczynski, Mariusz
AU  - Skwarczynski M
AD  - School of Chemistry and Molecular Biosciences, The University of Queensland, St 
      Lucia, QLD 4072, Australia.. Australia.
FAU - Toth, Istvan
AU  - Toth I
AD  - School of Chemistry & Molecular Biosciences, School of Pharmacy, University of 
      Queensland, Chemistry Blg #68, StLucia, Qld 4072, Australia.. Australia.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Med Chem
JT  - Medicinal chemistry (Shariqah (United Arab Emirates))
JID - 101240303
RN  - 0 (Lipopeptides)
RN  - 0 (Liposomes)
RN  - 0 (Streptococcal Vaccines)
SB  - IM
MH  - Animals
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Immunity, Mucosal/*immunology
MH  - Lipopeptides/*immunology
MH  - Liposomes/*immunology
MH  - Mice
MH  - Molecular Structure
MH  - Streptococcal Infections/immunology/*therapy
MH  - Streptococcal Vaccines/*immunology
MH  - Streptococcus pyogenes/*drug effects/immunology
MH  - Structure-Activity Relationship
OTO - NOTNLM
OT  - Peptide-based subunit vaccine
OT  - Streptococcus pyogenes
OT  - liposomes
OT  - mucosal immunity
OT  - self-adjuvanting.
EDAT- 2016/07/28 06:00
MHDA- 2017/08/30 06:00
CRDT- 2016/07/25 06:00
PHST- 2016/05/26 00:00 [received]
PHST- 2016/07/13 00:00 [revised]
PHST- 2016/07/13 00:00 [accepted]
PHST- 2016/07/28 06:00 [pubmed]
PHST- 2017/08/30 06:00 [medline]
PHST- 2016/07/25 06:00 [entrez]
AID - MC-EPUB-77168 [pii]
AID - 10.2174/1573406412666160720093138 [doi]
PST - ppublish
SO  - Med Chem. 2016;13(1):22-27. doi: 10.2174/1573406412666160720093138.